arrow
A

Anil Kumar Pandey

council of scientific & industrial research (csir) - india
H指数:19
被引数:1,422

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Immunogenicity and safety of Biological E's CORBEVAXTM vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELDTM or COVAXIN: A prospective double-blind randomized phase III clinical study
2025-10-011
OAAI
Severe SARS-CoV-2 infection in diabetes was rescued in mice supplemented with metformin and/or αKG, and patients taking metformin, via HIF1α-IFN axis

糖尿病小鼠补充二甲双胍和/或αKG以及服用二甲双胍的患者中,严重SARS-CoV-2感染通过HIF1α-IFN轴得到挽救。

2025-04-080
OAAI
Understanding the landscape of the SARS-CoV-2-specific T cells post-omicron surge

了解omicron激增后SARS-CoV-2-specific T细胞的景观

2024-08-210
PRE
Severity and mortality associated with COVID-19 among children hospitalised in tertiary care centres in India: a cohort study
2023-06-018
OAAI
Immunogenicity and safety of Biological E's CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial
2023-04-2717
OAAI
Diabetes mellitus, maternal adiposity, and insulin-dependent gestational diabetes are associated with COVID-19 in pregnancy: the INTERCOVID study

糖尿病,孕妇肥胖和胰岛素依赖型妊娠糖尿病与妊娠新型冠状病毒肺炎有关: INTERCOVID研究

2022-07-0149
OAAI
Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months
2022-04-0144
OAAI
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial
LANCET
IF88.5
2021-12-01229
OAAI
Development of a Fast SARS-CoV-2 IgG ELISA, Based on Receptor-Binding Domain, and Its Comparative Evaluation Using Temporally Segregated Samples From RT-PCR Positive Individuals
2021-01-2027
OAAI